

# LONG-TERM REAL-WORLD EXPERIENCE WITH TYSABRI<sup>1</sup>



**THE POWER YOU NEED  
THE EXPERIENCE YOU TRUST**  
FOR YOUR HIGHLY ACTIVE RRMS PATIENTS

**230,000+**  
patients treated  
with TYSABRI  
globally\*<sup>1</sup>

**>920,000**  
patient-years  
of exposure\*<sup>1</sup>



References: **1.** Biogen, data on file: Global Natalizumab (TYSABRI) Postmarketing PML Update. July 2021.

\* Biogen data on file, as of July 2021.

© 2021 Biogen. All rights reserved, Biogen-149684. Date of preparation: December 2021.

